Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on Efgartigimod for Patients with Antibody-Mediated Rejection after Kidney Transplant

Fast replyRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying a condition known as Antibody-Mediated Rejection, which can occur in individuals who have received a kidney transplant. This condition happens when the body's immune system mistakenly attacks the transplanted kidney, thinking it is a foreign object. The study will test a treatment called Efgartigimod, which is given as a solution for injection using a pre-filled syringe. Efgartigimod is designed to help reduce the immune system's attack on the transplanted kidney.

The purpose of the study is to evaluate the safety and tolerability of Efgartigimod in people who have experienced antibody-mediated rejection after a kidney transplant. Participants in the study will receive either Efgartigimod or a placebo, which looks like the treatment but does not contain the active medication. The study will be conducted over a period of time, during which participants will receive regular injections and attend follow-up visits to monitor their health and the effects of the treatment.

Throughout the study, various health assessments will be conducted, including checking for any side effects, monitoring kidney function, and measuring levels of certain proteins in the blood. The study aims to gather information on how well Efgartigimod works in managing antibody-mediated rejection and its overall impact on the health of kidney transplant recipients. Participants will be closely monitored by healthcare professionals to ensure their safety and well-being during the trial.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, you will be informed about the purpose and procedures of the trial. You will be asked to provide consent to participate.

    You will be required to confirm that you meet the eligibility criteria, such as being between 18 and 80 years old, having had a kidney transplant at least 6 months ago, and having a diagnosis of active or chronic active antibody-mediated rejection.

  2. Step 2

    Initial assessment

    An initial assessment will be conducted to evaluate your current health status. This may include laboratory tests, vital sign measurements, and an electrocardiogram (ECG).

    Your current medications will be reviewed to ensure they meet the study requirements, such as having been on a stable dose of mycophenolate mofetil and tacrolimus for at least 4 weeks.

  3. Step 3

    Treatment administration

    You will receive the study medication, efgartigimod, or a placebo through a subcutaneous injection using a prefilled syringe.

    The dosage and frequency of administration will be determined by the study protocol, and you will be informed about the schedule.

  4. Step 4

    Ongoing monitoring

    Throughout the study, you will be monitored for any side effects or adverse events. Regular check-ups will be scheduled to assess your health and the effectiveness of the treatment.

    Laboratory tests, vital sign measurements, and ECGs will be conducted periodically to ensure your safety.

  5. Step 5

    Follow-up assessments

    Follow-up assessments will be conducted to evaluate the impact of the treatment on your kidney function and overall health.

    These assessments may include measuring changes in kidney biopsy results, urine protein levels, and serum IgG levels.

  6. Step 6

    Completion of the study

    At the end of the study, a final assessment will be conducted to gather data on your health status and the outcomes of the treatment.

    You will be informed about the results of the study and any further steps, if necessary.

Who can join the trial?

7 criteria

  • The participant is between the ages of 18 and 80 years old.
  • The participant had a kidney transplant (from a living or deceased donor) at least 6 months before the screening.
  • The participant has been diagnosed with active or chronic active antibody-mediated rejection (AMR) and has detectable donor-specific antibodies at the time of screening.
    (Antibodies are proteins made by the immune system to fight infections. In this case, they are specific to the donor's kidney.)
  • The participant may be allowed into the study if they have received the following medications:
    • Received mycophenolate mofetil (MMF) for at least 20 weeks before screening.
      (MMF is a medication that helps prevent the body from rejecting a transplanted organ.)
    • Has remained on a stable dose of mycophenolate mofetil (MMF) and tacrolimus (TAC) for at least 4 weeks before being allowed to participate in the study.
      (Tacrolimus is another medication used to prevent organ rejection.)
    • Has remained on tacrolimus (TAC) doses between 5 to 10 ng/mL for at least 4 weeks before being allowed to participate in the study.
    • The steroid dose was between 0 to 10 mg per day of prednisone (or an equivalent dose) for at least 4 weeks before being allowed to participate in the study.
      (Steroids like prednisone are used to reduce inflammation and help prevent organ rejection.)

Who cannot join the trial?

5 criteria

  • Patients who are not diagnosed with Antibody-Mediated Rejection cannot participate.
  • Patients who are not within the specified age range cannot participate.
  • Patients who are not part of the specified clinical trial group cannot participate.
  • Patients who are not male or female cannot participate.
  • Patients who are not considered part of a vulnerable population cannot participate.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Efgartigimod PH20 SC is a medication being tested in this clinical trial. It is designed to help people who have received a kidney transplant and are experiencing a condition called antibody-mediated rejection (AMR). This condition occurs when the body's immune system attacks the new kidney. Efgartigimod PH20 SC is given through a prefilled syringe and works by reducing the activity of certain antibodies in the body that are responsible for this rejection. The goal of the trial is to see if this medication is safe and well-tolerated by patients, and to understand how effective it is in helping to manage or reduce the rejection of the transplanted kidney.

What is already known about the treatment

Efgartigimod PH20 SC – This medication is administered through a prefilled syringe, designed for subcutaneous injection, meaning it is injected under the skin. It is currently being studied in a Phase 2 clinical trial to assess its safety and effectiveness in kidney transplant recipients who experience antibody-mediated rejection, a condition where the immune system attacks the transplanted kidney. Efgartigimod works by targeting and reducing specific antibodies in the body that contribute to this rejection process. It belongs to a class of drugs known as immunomodulators, which help regulate or normalize the immune system's response.

Investigated diseases

Antibody-Mediated Rejection – Antibody-Mediated Rejection (AMR) is a condition that occurs when the immune system attacks a transplanted organ, such as a kidney, due to the presence of antibodies against the donor's tissue. This immune response leads to inflammation and damage to the blood vessels in the transplanted organ. Over time, the ongoing immune attack can impair the function of the transplanted organ. The progression of AMR can vary, with some cases being acute and others chronic. Acute AMR can occur shortly after transplantation, while chronic AMR develops over a longer period. The condition requires careful monitoring to assess the extent of organ damage and immune activity.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IITrial ID2023-508180-72-00Protocol codeARGX-113-2302Estimated enrolment30 patientsSponsorArgenx

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).